Multiple Chinese Pharma Companies Announce New Drug Approvals in November, Strengthening Market Competitiveness

　　【Pharmaceutical Network Product Information】The pharmaceutical industry is an important industry related to the national economy and people's livelihood. It is an essential support for meeting the health needs of the people, ensuring national health security, and building a strong public health system. The approval and market launch of drugs are of great significance to patients. At the same time, the approval and market launch of drugs also have important implications for a company, as it not only further enriches the company’s product portfolio and enhances its market competitiveness but also positively impacts the company’s performance. According to reports, since entering November, several pharmaceutical companies have announced the approval and market launch of new drugs, bringing positive news to the market.
 

　　Four Rings Pharmaceutical Clopidogrel Bisulfate Tablets (75 mg) Approved for Production and Market Launch
 

On November 9, Sinopharm announced at noon that the group's developed Clopidogrel Bisulfate Tablets (75 mg) ("the product") had received the production approval from the National Medical Products Administration of China, allowing the product to be produced and considered to have passed the quality and efficacy consistency evaluation for generic drugs.
 

Clopidogrel Bisulfate Tablets are a platelet aggregation inhibitor and an antithrombotic drug. This product has strong antiplatelet effects and high safety, making it a first-line treatment for stroke, myocardial infarction, and other peripheral arterial diseases. The product is classified under Category B of China's National Medical Insurance and is included in the national centralized procurement list.
 

The announcement states that the cardiovascular and cerebrovascular field is a key focus area for the group. The approval and market launch of Clopidogrel Bisulfate Tablets (75 mg) will further benefit a large number of patients, while adding a significant product to the group’s cardiovascular and cerebrovascular drug pipeline. This will enhance the future market sales and competitiveness of the drug, positively impacting the group’s operating performance.
 

　　Lummy Pharmaceutical's Antifungal Drug Voriconazole Tablets Approved
 

On November 9, Laimei Pharmaceuticals announced that its broad-spectrum triazole antifungal drug Voriconazole Tablets (50mg and 0.2g) have been approved. At the same time, Voriconazole produced by Chongqing Laimei Longyu Pharmaceuticals has also been approved.Active Pharmaceutical IngredientsUsed in this preparation.
 

Voriconazole Tablets are mainly used for the treatment of progressive, potentially life-threatening fungal infections in patients, including invasive aspergillosis, candidemia in non-neutropenic patients, serious invasive infections caused by fluconazole-resistant Candida, and severe infections caused by Scedosporium and Fusarium species. They are also used for the prevention of invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation.
 

　　Dongyang Light Medicine's Insulin Glargine Injection Approved for Marketing
 

Dongyang Light Medicine recently announced that its self-developed product, Insulin Glargine Injection, has been approved by the China National Medical Products Administration and is now authorized for market release.
 

Insulin Glargine belongs to human insulin analogs, with a long-acting blood sugar lowering effect, and is suitable for treating diabetic patients who need insulin to maintain normal blood glucose levels.
 

The successful approval and market launch of this product will help expand Dongyangguang Pharmaceutical Group's business in the field of endocrinology and metabolism treatment, and further enrich the group's product portfolio. In addition, the company expects that all remaining products under development will be approved within this year, and two new drugs are expected to be launched between 2023 and 2024.
 

　　Qilu Pharmaceutical's Cisplatin Injection and Caspofungin Acetate for Injection Approved for Marketing
 

Recently, Qilu Pharmaceutical's Cisplatin Injection and Caspofungin Acetate for Injection have been approved by the National Medical Products Administration (NMPA) for marketing in China and are considered to have passed the consistency evaluation.
 

Cisplatin is a heavy metal complex with anticancer effects. Clinically, it can be used alone or in combination with other chemotherapeutic drugs for the palliative treatment of small cell and non-small cell lung cancer, advanced refractory ovarian cancer, gastric cancer, esophageal cancer, etc. As a first-generation platinum-based antitumor drug, cisplatin injection has the characteristics of a broad anticancer spectrum, high anticancer activity, and predictable and controllable toxic side effects, making it widely used in clinical applications.
 

Caspofungin acetate belongs to the echinocandin class of semisynthetic lipopeptides and is an antifungal drug with a novel mechanism of action. It exerts its fungicidal effect by inhibiting the synthesis of the cell wall in susceptible fungi. Clinically, it is used to treat suspected fungal infections in neutropenic patients with fever and invasive aspergillosis that is either resistant to other treatments or cannot be tolerated. It has a broad antifungal spectrum, excellent efficacy, and good hepatic tolerance, making it an effective drug for deep-seated fungal infections.
 

　Meno Hua Luosartan Potassium Tablets Approved for Marketing
 

Recently, Meinov announced that Ningbo Corek Meinov Pharmaceutical Co., Ltd. ("Corek Meinov"), jointly invested by the company and European pharmaceutical enterprise KRKA D.D., NOVO MESTO ("KRKA"), has recently received the "Losartan Potassium Tablets" 《Drug Registration Certificate》 issued by the National Medical Products Administration. This drug is used for the treatment of essential hypertension.
 

The acquisition of the "Drug Registration Certificate" for Losartan Potassium Tablets from the National Medical Products Administration marks that Corecon Menaury has obtained the qualification to produce and sell this drug in the Chinese market. Moreover, the active pharmaceutical ingredients required for the production of this drug are provided by the company's subsidiary, Zhejiang Menaury Pharmaceutical Chemistry Co., Ltd. This will further diversify the company’s product portfolio, enhance its market competitiveness, and have a positive impact on the company’s performance.